Prometheus Laboratories Inc., a specialty pharmaceutical company announced today that it has launched PROMETHEUS IBD Serology 7, the Company's most advanced diagnostic panel for inflammatory bowel disease. With an overall
accuracy of 92%, this unprecedented diagnostic test is the most comprehensive
IBD test available with proprietary markers to help physicians diagnose inflammatory
bowel disease ("IBD") and to differentiate the subtypes of Crohn's disease
and ulcerative colitis.